The proposed agreement would grant Jupiter Neurosciences exclusive U.S. rights to PharmAla’s lead psychedelic drug candidate while allowing PharmAla to retain international commercialization rights.

Harbour BioMed will receive $105 million upfront, consisting of $50 million cash, $5 million in near-term payments and more than $50 million of equity in Solstice Oncology. (iStock/Getty Images Plus) ...

HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent expirations, with industry analysts ...

AlzeCure Pharma said on Wednesday it had entered an out-licensing and partnership ​deal with Danish biotech QuantumCell ApS ‌valued at more than $2.2 billion, excluding royalty payments.

Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics Provided by PR Newswire Feb 24, 2026, 2:55:00 AM Frontier Biotech and GSK Enter Global ...

As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to block those deals have gotten louder. By relying on China to fuel pipelines, ...

A patent grant, a trademark registration, or a portfolio of carefully guarded trade secrets represents potential value — but that value is ...

Deal-making between U.S. and Chinese biopharma companies continued this week, with the California-based biotech Travere Therapeutics (TVTX) announcing a licensing agreement worth up to $1.1B with ...

HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent expirations, with industry analysts ...